Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引：3

作者：

Sznol, M. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Hogg, D. ^{[3
]}

Atkins, M. ^{[4
]}

Wolter, P. ^{[5
]}

Guidoboni, M. ^{[6
]}

Lebbe, C. ^{[7
]}

Kirkwood, J. ^{[8
]}

Schachter, J. ^{[9
]}

Daniels, G. ^{[10
]}

Hassel, J. ^{[11
]}

Cebon, J. ^{[12
]}

Gerritsen, W. ^{[13
]}

Atkinson, V. ^{[14
,15
]}

Thomas, L. ^{[16
]}

McCaffrey, J. ^{[17
]}

Power, D. ^{[18
]}

Jiang, J. ^{[19
]}

Hodi, F. S. ^{[20
]}

Wolchok, J. ^{[21
]}

机构：

[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy

[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA

[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium

[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy

[7] Hop St Louis, Dermatol, Paris, France

[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA

[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA

[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany

[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia

[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands

[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia

[15] Princess Alexandra Hosp, Greenslopes, Australia

[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France

[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland

[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland

[19] BMS, Oncol, Princeton, NJ USA

[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA

[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1123P

引用

页数：1

共 50 条

[1] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
Sznol, Mario
Ferrucci, Pier
Hogg, David
Atkins, Michael
Wolter, Pascal
Guidoboni, Massimo
Lebbe, Celeste
Kirkwood, John
Schachter, Jacob
Daniels, Gregory
Hassel, Jessica
Cebon, Jonathan
Gerritsen, Winald
Atkinson, Victoria
Thomas, Luc
Mccaffrey, John
Power, Derek
Jiang, Joel
Hodi, Stephen
Wolchok, Jedd
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
[2] SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)
Chapman, Paul B.
Sznol, Mario
Lao, Christopher D.
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini R.
Sharfman, William H.
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin B.
Weber, Jeffrey S.
Nair, Suresh
Cowey, Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 119 - 119
[3] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
Chapman, Paul B.
Sznol, Mario
Lao, Christopher
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini Reiney
Sharfman, William Howard
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin
Weber, Jeffrey S.
Patel, Sapna Pradyuman
Nair, Suresh
Cowey, C. Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
Robert, Caroline
Larkin, James
Ascierto, Paolo A.
Long, Georgina V.
Hassel, Jessica C.
Schadendorf, Dirk
Hodi, F. Stephen
Lebbe, Celeste
Grob, Jean-Jacques
Grossmann, Kenneth
Wagstaff, John
Chesney, Jason
Hogg, David
Bechter, Oliver
Marquez-Rodas, Ivan
Pavlick, Anna C.
DanaWalker
Bhore, Rafia
Postow, Michael A.
Wolchok, Jedd D.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
[5] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
Robert, C.
Larkin, J.
Ascierto, P. A.
Long, G. V.
Hassel, J. C.
Schadendorf, D.
Hodi, F. S.
Lebbe, C.
Grob, J-J.
Grossmann, K.
Wagstaff, J.
Chesney, J.
Hogg, D.
Bechter, O.
Marquez-Rodas, I.
Pavlick, A. C.
Walker, D.
Bhore, R.
Postow, M. A.
Wolchok, J. D.
ANNALS OF ONCOLOGY, 2017, 28
[6] Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
Weber, Jeffrey S.
Antonia, Scott Joseph
Topalian, Suzanne Louise
Schadendorf, Dirk
Larkin, James M. G.
Sznol, Mario
Liu, Helen Y.
Waxman, Ian
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.
Warner, Allison Betof
Shoushtari, Alexander Noor
Houghton, Sean
Panageas, Katherine
Chapman, Paul B.
Wolchok, Jedd D.
Postow, Michael A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA
Statkevich, P.
Passey, C.
Park, J.
Saeger, S.
Bello, A.
Roy, A.
Agrawal, S.
Gupta, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S64 - S64
[9] The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM).
Patel, Sapna Pradyuman
Glitza, Isabella Claudia
Diab, Adi
Amaria, Rodabe Navroze
Davies, Michael A.
Hwu, Patrick
Tawbi, Hussein Abdul-Hassan
Hwu, Wen-Jen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA.
Statkevich, P.
Passey, C.
Park, J.
Saeger, S.
Bello, A.
Roy, A.
Agrawal, S.
Gupta, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S9 - S9

← 1 2 3 4 5 →